These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 25788388

  • 1. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
    Yashima Y, Sato S, Kawai T, Sugimoto T, Sato T, Kanda M, Obi S.
    Hepatol Int; 2015 Jan; 9(1):142-8. PubMed ID: 25788388
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
    Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y.
    Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, Pennucci C, Sanguinetti F, Lombardi M, Nicoli N.
    Cancer; 2005 Apr 01; 103(7):1402-7. PubMed ID: 15726542
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
    Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C.
    J Clin Oncol; 1996 Aug 01; 14(8):2311-5. PubMed ID: 8708722
    [Abstract] [Full Text] [Related]

  • 6. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ.
    Ann Oncol; 2004 May 01; 15(5):770-4. PubMed ID: 15111345
    [Abstract] [Full Text] [Related]

  • 7. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
    Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N.
    Jpn J Clin Oncol; 2006 Sep 01; 36(9):552-6. PubMed ID: 16887837
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Cancer; 2012 Jul 01; 118(13):3302-10. PubMed ID: 22072099
    [Abstract] [Full Text] [Related]

  • 9. Time to move to targeted drugs in biliary tract cancer?
    Louvet C, Tournigand C.
    Onkologie; 2010 Jul 01; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract] [Full Text] [Related]

  • 10. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
    Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD.
    Cancer Chemother Pharmacol; 2011 Dec 01; 68(6):1595-602. PubMed ID: 21556747
    [Abstract] [Full Text] [Related]

  • 11. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience.
    Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K, Takeda K.
    Eur J Radiol; 2002 Jan 01; 41(1):42-8. PubMed ID: 11750151
    [Abstract] [Full Text] [Related]

  • 12. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
    Tanaka K, Yabushita Y, Nakagawa K, Kumamoto T, Matsuo K, Taguri M, Endo I.
    Eur J Surg Oncol; 2013 Dec 01; 39(12):1364-70. PubMed ID: 24183169
    [Abstract] [Full Text] [Related]

  • 13. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q.
    Med Oncol; 2015 Mar 01; 32(3):65. PubMed ID: 25691293
    [Abstract] [Full Text] [Related]

  • 14. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM, Lee WJ, Han SS, Park SJ, Kim TH, Koh YH, Kim HB, Hong EK, Park JW, Kim CM.
    Chemotherapy; 2012 Mar 01; 58(3):225-32. PubMed ID: 22831988
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
    Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K.
    J Gastroenterol; 2007 Oct 01; 42(10):845-53. PubMed ID: 17940838
    [Abstract] [Full Text] [Related]

  • 16. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H, Kirikoshi H, Yoneda M, Higurashi T, Fujita K, Saito S, Inamori M, Takahashi H, Abe Y, Kubota K, Nakajima A.
    Hepatogastroenterology; 2008 Oct 01; 55(86-87):1776-7. PubMed ID: 19102391
    [Abstract] [Full Text] [Related]

  • 17. [Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
    Wada H, Nagano H, Dono K, Kondo M, Yamamoto T, Ota H, Nakamura M, Yoshioka S, Damdinsuren B, Yubo Y, Marubashi S, Miyamoto A, Umeshita K, Nakamori S, Sakon M, Monden M.
    Gan To Kagaku Ryoho; 2004 Oct 01; 31(11):1711-3. PubMed ID: 15553691
    [Abstract] [Full Text] [Related]

  • 18. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.
    Smith GW, Bukowski RM, Hewlett JS, Groppe CW.
    Cancer; 1984 Oct 15; 54(8):1513-6. PubMed ID: 6089991
    [Abstract] [Full Text] [Related]

  • 19. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K, Yamasaki T, Hamabe S, Saeki I, Harima Y, Terai S, Sakaida I.
    Hepatogastroenterology; 2012 Oct 15; 59(114):533-7. PubMed ID: 22353519
    [Abstract] [Full Text] [Related]

  • 20. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
    Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K.
    J Gastroenterol; 2012 Oct 15; 47(10):1152-9. PubMed ID: 22438097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.